viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals receives positive results from ArtemiC pre-clinical testing with no pathological impact on major organs

Results provide critical additional information on the toxicological evaluation of ArtemiC regarding its effect on organs that were studied and augment base data supporting the current Phase IIa clinical trial on COVID-19 patients and future clinical studies.

MGC Pharmaceuticals Ltd - MGC Pharmaceuticals receive positive results from ArtemiCTM pre-clinical testing with no pathological impact on major organs
This completes the FDA requirements for toxicology tests for new drug development

MGC Pharmaceuticals Ltd (ASX:MXC) has received positive results from a pre-clinical in vivo safety and toxicity study, including histology testing, of ArtemiCTM on rats with no pathological changes or differences between the study groups reported.

These positive results demonstrating no pathological impact on major organs of the animals in the study are significant as this completes the FDA requirements for toxicology tests for new drug development.

MGC Pharma co-founder and managing director Roby Zomer said: “The histology results provide the company with important insights into the potential effects of ArtemiCTM on major organs.

“Pleasingly, no adverse impacts were recorded on major organs which provides critical information in relation to planning for future clinical studies.”

ArtemiCTM results

Following the safety and toxicity testing completed on mice in July and in line with FDA requirements for product registration requiring two types of rodents in pre-clinical trials, MGC Pharma completed an in vivo safety and toxicity pre-clinical study, including histology testing, on 24 rats.

This included four groups with three 3 study drug dosages being 48ug, 96ug and 196ug per kg rat and a control group.

The rats were observed and tested for clinical changes over seven days which included pathological examination of the organs - liver, heart, brain, spleen, spinal cord, sciatic nerve, kidney (L+R), lungs and tongue.

The results concluded there were no pathological changes in all tested animal samples, which is a promising outcome for the company and its ongoing clinical trial and studies on ArtemiCTM.

Treating COVID-19

ArtemiCTM is designed with the scientific aim to target inflammatory complications due to dysregulation of the immune response (cytokine storm) which may cause organ damage and lung complications from COVID19.

The drug is currently being evaluated in a Phase IIa clinical trial on COVID-19 infected patients in Israel.

This pre-clinical data on rats will support future efficacy clinical studies in Phase IIb and Phase III in COVID-19 patients.

The Phase IIb study will include efficacy endpoints and dose-finding elements, based on these current animal study results.

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.024 AUD

Market: ASX
Market Cap: $39.38 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...


MGC Pharmaceuticals launches new CannEpil® App

MGC Pharmaceuticals Ltd (ASX:MXC) co-founder and MD Roby Zomer speaks to Proactive about the launch of its new CannEpil® app. The app is designed to collect patient data and provides medical professionals with access to the International Library of Cannabinoids (ILC) as part of its...

1 week, 5 days ago

2 min read